Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Severe Fever with Thrombocytopenia Syndrome (SFTS) is a new emerging tick-borne disease caused by the phlebovirus, SFTS virus (SFTSV). The virus was discovered in central China in 2009 and has since been identified in both Japan and South Korea. Significant progress has been made on the molecular biology of the virus, and this has been used to develop diagnostic assays and reagents. Less progress has been made on the epidemiology, maintenance and transmission, clinical manifestations, immunological responses, and treatment regimens. A number of animal models have been investigated but, to date, none recapitulate all the clinical manifestations seen in humans. Vaccine development is at an early discovery phase.

Original languageEnglish (US)
Pages (from-to)72-78
Number of pages7
JournalCurrent Opinion in Virology
Volume29
DOIs
StatePublished - Apr 1 2018

Fingerprint

Thrombocytopenia
Fever
Vaccines
Viruses
Phlebovirus
Tick-Borne Diseases
Republic of Korea
Molecular Biology
China
Japan
Epidemiology
Animal Models
Maintenance
Therapeutics

ASJC Scopus subject areas

  • Virology

Cite this

@article{a839750264b24355b10c1e307d39bee3,
title = "Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development",
abstract = "Severe Fever with Thrombocytopenia Syndrome (SFTS) is a new emerging tick-borne disease caused by the phlebovirus, SFTS virus (SFTSV). The virus was discovered in central China in 2009 and has since been identified in both Japan and South Korea. Significant progress has been made on the molecular biology of the virus, and this has been used to develop diagnostic assays and reagents. Less progress has been made on the epidemiology, maintenance and transmission, clinical manifestations, immunological responses, and treatment regimens. A number of animal models have been investigated but, to date, none recapitulate all the clinical manifestations seen in humans. Vaccine development is at an early discovery phase.",
author = "Reece, {Lisa M.} and David Beasley and Gregg Milligan and Vanessa Sarathy and Alan Barrett",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.coviro.2018.03.005",
language = "English (US)",
volume = "29",
pages = "72--78",
journal = "Current Opinion in Virology",
issn = "1879-6257",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development

AU - Reece, Lisa M.

AU - Beasley, David

AU - Milligan, Gregg

AU - Sarathy, Vanessa

AU - Barrett, Alan

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Severe Fever with Thrombocytopenia Syndrome (SFTS) is a new emerging tick-borne disease caused by the phlebovirus, SFTS virus (SFTSV). The virus was discovered in central China in 2009 and has since been identified in both Japan and South Korea. Significant progress has been made on the molecular biology of the virus, and this has been used to develop diagnostic assays and reagents. Less progress has been made on the epidemiology, maintenance and transmission, clinical manifestations, immunological responses, and treatment regimens. A number of animal models have been investigated but, to date, none recapitulate all the clinical manifestations seen in humans. Vaccine development is at an early discovery phase.

AB - Severe Fever with Thrombocytopenia Syndrome (SFTS) is a new emerging tick-borne disease caused by the phlebovirus, SFTS virus (SFTSV). The virus was discovered in central China in 2009 and has since been identified in both Japan and South Korea. Significant progress has been made on the molecular biology of the virus, and this has been used to develop diagnostic assays and reagents. Less progress has been made on the epidemiology, maintenance and transmission, clinical manifestations, immunological responses, and treatment regimens. A number of animal models have been investigated but, to date, none recapitulate all the clinical manifestations seen in humans. Vaccine development is at an early discovery phase.

UR - http://www.scopus.com/inward/record.url?scp=85049379178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049379178&partnerID=8YFLogxK

U2 - 10.1016/j.coviro.2018.03.005

DO - 10.1016/j.coviro.2018.03.005

M3 - Review article

C2 - 29642053

AN - SCOPUS:85049379178

VL - 29

SP - 72

EP - 78

JO - Current Opinion in Virology

JF - Current Opinion in Virology

SN - 1879-6257

ER -